CERO THERAPEUTICS HOLDINGS, INC.
CERO THERAPEUTICS HOLDINGS, INC.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series Seed | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Related Party | - | - | - | - | - | - | - | - | - | 2 | - | - | |||||
Cash | - | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Assets Held In Trust Current | - | - | - | - | - | - | - | - | - | 8 | 8 | 14 | |||||
Restricted Cash And Cash Equivalents At Carrying V… | - | - | - | 3 | 5 | - | - | - | - | - | - | - | |||||
Cash And Cash Equivalents At Carrying Value | 1 | 2 | 2 | - | - | 3 | 3 | 4 | 5 | 2 | 0 | - | |||||
Assets Current | |||||||||||||||||
Assets Current | 2 | 3 | 3 | 4 | 6 | 4 | 4 | 4 | 6 | 2 | - | - | |||||
Other Receivables Net Current | - | - | - | - | - | - | - | 0 | 0 | - | - | - | |||||
Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | |||||
Deferred Costs Current | - | - | - | - | - | 0 | - | - | - | - | - | - | |||||
Equity Securities Fv Ni | - | - | - | 1 | - | - | - | - | - | - | - | - | |||||
Deferred Costs | - | - | 0 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | |||||
Operating Lease Right Of Use Asset | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | - | - | |||||
Taxes Payable Current | - | - | - | - | - | - | - | - | - | 0 | - | - | |||||
Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | - | - | |||||
Assets | 2 | 4 | 4 | 6 | 8 | 6 | 6 | 7 | 9 | 5 | 8 | 14 | |||||
Accounts Payable Current | 8 | 8 | 7 | 6 | 6 | 5 | 7 | 6 | 7 | 2 | 3 | 3 | |||||
Accrued Income Taxes Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | |||||
Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 1 | 1 | |||||
Accrued Liabilities Current | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | - | - | |||||
Long Term Debt And Capita… | |||||||||||||||||
Deferred Revenue Noncurrent | - | - | - | - | - | - | - | - | - | 9 | - | - | |||||
Liabilities Current | |||||||||||||||||
Finance Lease Liability Current | 0 | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Liabilities Current | 11 | 9 | 8 | 8 | 8 | 7 | 9 | 9 | 12 | 4 | 5 | 4 | |||||
Operating Lease Liability Current | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | |||||
Short Term Bank Loans And Notes Payable | - | - | - | - | - | - | 0 | 0 | 0 | 1 | - | - | |||||
Redeemable Noncontrolling… | |||||||||||||||||
Temporary Equity Carrying Amount Attributable To P… | - | - | - | - | - | - | - | - | - | 8 | 8 | 14 | |||||
Warrants And Rights Outstanding | - | - | - | - | - | - | - | - | - | 0 | - | - | |||||
Derivative Liabilities Current | 2 | - | - | - | - | - | - | - | - | - | - | - | |||||
Dividends Payable Current | 0 | 0 | - | - | - | 0 | - | - | - | - | - | - | |||||
Long Term Liabilities | |||||||||||||||||
Operating Lease Liability Noncurrent | - | - | - | 0 | 0 | 1 | 1 | 1 | 1 | 2 | - | - | |||||
Liabilities Noncurrent | |||||||||||||||||
Convertible Debt Noncurrent | 0 | - | - | - | - | - | - | - | - | - | - | - | |||||
Liabilities | 11 | 9 | 8 | 8 | 8 | 8 | 10 | 10 | 13 | 5 | 14 | 14 | |||||
Redeemable Common Stock | |||||||||||||||||
Common Stock Value | - | - | - | - | - | - | - | - | - | 0 | - | 0 | |||||
Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Additional Paid In Capital | 80 | 78 | 73 | 71 | 73 | 67 | 66 | 58 | 54 | 1 | - | - | |||||
Stockholders Equity | |||||||||||||||||
Stockholders Equity | -9 | -5 | -5 | -2 | -0 | -2 | -4 | -2 | -4 | -42 | -14 | -13 | |||||
Temporary Equity Shares Authorized | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | |||||
Temporary Equity Redemption Price Per Share | - | - | - | - | - | - | - | - | - | 11.03 | 10.83 | 10.74 | |||||
Stockholders Equity Note Subscriptions Receivable | -0 | - | - | -0 | -0 | -1 | -2 | -2 | -3 | - | - | - | |||||
Retained Earnings Accumulated Deficit | -97 | -91 | -86 | -81 | -76 | -71 | -72 | -67 | -65 | -43 | -14 | -13 | |||||
Liabilities And Stockholders Equity | 2 | 4 | 4 | 6 | 8 | 6 | 6 | 7 | 9 | 5 | 8 | 14 | |||||
Series A | - | - | - | - | - | - | - | - | - | 25 | - | - | |||||
Common Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | 0 | - | - | |||||
Common Stock Shares Authorized | - | - | - | - | - | - | - | - | - | 45 | - | - | |||||
Common Stock Shares Issued | - | - | - | - | - | - | - | - | - | 0 | - | - | |||||
Shares Outstanding | - | - | - | - | - | - | - | - | - | 0 | - | - | |||||
Series C Convertible Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | |||||
Series D Convertible Preferred Stock | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | - | |||||
Series E Convertible Preferred Stock | 0 | 0 | - | - | - | 0 | - | - | - | - | - | - | |||||
Series B Convertible Preferred Stock | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | |||||
Common Class B | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | |||||
Assets | |||||||||||||||||
Series A Convertible Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | |||||
Common Class A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 6 | |||||
Other Liabilities Current | 0 | 0 | - | - | - | 0 | - | - | - | - | - | - | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | - | - | - | 0 | - | - | - | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 10 | 10 | - | - | - | 10 | - | - | - | 1 | 1 | 1 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -55.56% | -55.56% | -62.96% | - | - | - | - | - | - | - | - | - |
| 2025 | -22.09% | -20.72% | -34.29% | -34.94% | -60.12% | -98.55% | 83.33% | -16.67% | -20.00% | -9.38% | -62.50% | -62.50% |
| 2024 | -38.82% | -76.91% | -85.73% | -29.05% | -37.16% | -43.92% | -77.11% | -88.11% | -92.21% | 11.11% | -22.22% | -20.85% |
| 2023 | - | - | - | -1.28% | -0.64% | -0.73% | 0.00% | 1.20% | 1.56% | -38.01% | -58.46% | -84.39% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Metrics | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 0.14 | 0.30 | 0.30 | 0.56 | 0.73 | 0.50 | 0.39 | 0.48 | 0.47 | 0.56 | - | - | |||||
| Quick Ratio | 0.08 | 0.18 | 0.24 | 0.50 | 0.66 | 0.46 | 0.36 | 0.43 | 0.41 | 0.46 | - | - | |||||
| Working Capital | -9.75M | -6.35M | -5.90M | -3.37M | -2.09M | -3.69M | -5.71M | -4.53M | -6.15M | -1.54M | - | - | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | -1.24 | -1.67 | -1.86 | -4.80 | -25.26 | -4.28 | -2.75 | -3.97 | -3.28 | -0.12 | -1.01 | -1.02 | |||||
| Interest Coverage TTM | -94.17 | -625.66 | -293.49 | -302.57 | -292.97 | -217.86 | -126.47 | -105.37 | -58.20 | -55.47 | -135.59 | -124.19 | |||||
| Debt Ratio | 5.20 | 2.50 | 2.16 | 1.26 | 1.04 | 1.31 | 1.57 | 1.34 | 1.44 | 0.99 | - | - | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -0.71 | -4.71 | -19.36 | -35.27 | -83.11 | -7.26 | -0.40 | -0.86 | -932.33 | -24.97 | -13.55 | -10.39 | |||||
| Free Cash Flow Per Share TTM | 0.10 | -1.05 | -3.51 | -9.11 | -25.94 | -3.07 | -0.36 | -1.13 | -1,246.55 | -19.84 | -3.77 | -3.59 | |||||
| Dividend Per Share TTM | 0.00 | 0.02 | 0.07 | 0.17 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Growth Metrics | |||||||||||||||||
| Net Income Growth (1Y) | 42.88% | 89.41% | 149.56% | 148.20% | 116.51% | 44.28% | 59.75% | 47.27% | 141.15% | 991.69% | 753.64% | 484.89% | |||||
| EPS Growth (1Y) | -99.15% | -35.13% | 4,800.52% | 4,018.57% | -91.09% | -70.93% | -97.08% | -91.76% | 15,380.97% | 3,246.57% | 1,630.55% | 1,086.44% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -0.05 | -0.01 | -0.26 | -0.27 | -0.18 | -16.53 | -470.77 | -698.38 | -6.59 | -880.96 | -1,603.30 | -2,097.91 | |||||
| P/B TTM | -0.11 | -0.05 | -1.42 | -2.88 | -7.60 | -91.75 | -1,247.80 | -1,951.43 | -10.89 | -152.69 | -715.39 | -743.27 | |||||
| Market Cap | 1.01M | 283.40K | 6.44M | 4.70M | 2.50M | 173.83M | 4.62B | 4.84B | 43.33M | 6.42B | 9.85B | 9.88B | |||||
| Enterprise Value | 481.03K | -1.04M | 4.42M | 1.50M | -2.60M | 170.50M | 4.62B | 4.84B | 38.73M | 6.42B | 9.85B | 9.88B | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | 2.80M | -4.45M | -4.45M | -4.45M | -4.45M | -4.44M | -8.90M | -9.15M | -8.80M | -5.79M | -1.71M | -1.63M | |||||
| Net Debt | -525.40K | -1.32M | -2.02M | -3.20M | -5.10M | -3.33M | -3.38M | -3.65M | -4.59M | -1.60M | 1.28M | 1.07M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
CERO THERAPEUTICS HOLDINGS, INC. (CERO) — SEC Financial Statements & Analysis
CERO THERAPEUTICS HOLDINGS, INC. (CERO) is a biological products, (no diagnostic substances) company, incorporated in DE. CERO THERAPEUTICS HOLDINGS, INC. trades on OTC as: CERO, CEROW. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), CERO THERAPEUTICS HOLDINGS, INC. reported a Debt-to-Equity ratio of -1.24x, a Price-to-Book (P/B) ratio of -0.11 (TTM), at a market cap of $1.01M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- -1.24x
- P/B TTM
- -0.11
- Market Cap
- $1.01M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CERO THERAPEUTICS HOLDINGS, INC. in?
CERO THERAPEUTICS HOLDINGS, INC. (CERO) operates in the Biological Products, (No Diagnostic Substances) industry.
What is CERO's market cap?
CERO THERAPEUTICS HOLDINGS, INC. (CERO) has a market capitalization of $1.01M as of 2026-03-31.
What exchange does CERO trade on?
CERO THERAPEUTICS HOLDINGS, INC. (CERO) trades on the OTC.
Where is CERO THERAPEUTICS HOLDINGS, INC. incorporated?
CERO THERAPEUTICS HOLDINGS, INC. is incorporated in DE.